[1] JEMAL A,THOMAS A,MURRAY T,et al.Cancer statistics[J].CA Cancer J Clin,2012,62(1):10-29.
[2] ROBERTS R O,BERGSTRALH E J,KATUSIC S K,et al.Decline in prostate cancer mortality from 1980 to 1997,and an update on incidence trends in Olmsted County,Minnesota[J].J Urol,1999,161(2):529-533.
[3] JACOBSEN S J,KATUSIC S K,BERGSTRALH E J,et al.Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing[J].JAMA,1995,274(18):1445-1449.
[4] MANTOVANI A,ROMERO P,PALUCKA A K,et al.Tumour immunity:effector response to tumour and role of the microenvironment[J].Lancet,2008,371(9614):771-783.
[5] ALLAVENA P,GERMANO G,MARCHESI F,et al.Chemokines in cancer related inflammation[J].Experimental Cell Research,2011,317(5):664-673.
[6] de MARZO A M,PLATZ E A,SUTCLIFFE S,et al.Inflammation in prostate carcinogenesis[J].Nat Rev Cancer,2007,7(4):256-269.
[7] PALAPATTU G S,SUTCLIFFE S,BASTIAN P J,et al.Prostate carcinogenesis and inflam-mation: emerging insights[J].Carcinogenesis,2005,26(5):1170-1181.
[8] PRZYBYCIN C G,KUNJU L P,WU A J,et al.Partial atrophy in prostate needle biopsies:a detailed analysis of its morphology.immunophenotype and cellular kinetics[J].Am J Surg Pathol,2008,32(1):58-64.
[9] MACLENNAN G T,EISENBERG R,FLESHMAN R L,et al.The influence of chronic inflammation in prostatic carcinogenesis:a 5-year follow-up study[J].J Urol,2006,176(1):1012-1016.
[10] MAHMUD S M,TANGUAY S,BÉGIN L R,et al.Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population[J].Eur J Cancer Prev,2006,15(2):158-164.
[11] LIN H H,CHAN K C,SHEU J Y,et al.Hibiscus sabdariffa leaf induces apoptosis of human prostate cancer cells in vitro and in vivo[J].Food Chemistry,2012,132(2):880-891.
[12] HODOLICM,FETTICH J,CIMITAN M,et al.Unusual F-18 choline uptake in penile metastasis from prostate cancer[J].Clin Nucl Med,2012,37(4):e89-90.
[13] SUTCLIFFE S,GIOVANNUCCI E,de MARZO A M,et al.Gonorrhea,syphilis,clinical prostatitis and the risk of prostate cancer[J].Cancer Epidemiol Biomarkers Prev,2006,15(11):2160-2166.
[14] POSTMA R,SCHROEDER F H,van der KWAST T H,et al.Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men[J].Urology,2005,65(4):745-749.
[15] BILLIS A,FREITAS L L,MAGNA L A,et al.Inflammatory atrophy on prostate needle biopsies:is there topographic relation-ship to cancer?[J].Int Braz J Urol,2007,33(2):355-360.
[16] TOMAS D,KRUSLIN B,ROGATSCH H,et al.Different types of atrophy in the prostate with and without adenocarcinoma[J].Eur Urol,2007,51(1):98-103.
[17] MOYRET-LALLE C,MARC C,JACQUEMIER J,et al.ras,p53 and HPV status in benign and malignant prostate tumors[J].Int J Cancer,1995,64:124-129.
[18] PACE G,di MASSIMO C,de AMICIS D,et al.Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer[J].Int Braz J Urol,2011,37(5):617-622.
[19] WANG W,BERGH A,DAMBER J E.Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate[J].Prostate,2009,69(13):1378-1386.
[20] ROSENBLATT K A,WICKLUND K G,STANFORD J L.Sexual factors and the risk of prostate cancer[J].Am J Epidemiol,2011;153(1):1152-1158.
[21] ZHU X I,ALBERTSEN P C,ANDRIOLE G L,et al.Risk-based prostate cancer screening[J].Eeropean Urology,2012,61(4):652-661.
[22] BILLIS A,MEIRELLES L R,MAGNA L A,et al.Extent of prostatic atrophy in needle biopsies and serum PSA levels:is there an association?[J].Urology,2007,69(5):927-930.
[23] BARBISAN F,MAZZUCCHELLI R,SANTINELLI A,et al.Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy,high-grade prostatic intraepithelial neoplasia and incidental prostate cancer in cystoprostatectomies[J].Eur Urol,2009,56(1):105-112.
[24] 唐庆来,姚茂银,薛君,等.PSMA、PSA在前列腺腺癌组织中的表达及其与腺癌临床分期的相关性分析[J].东南大学学报:医学版,2010,29(1):65-69.
[25] 陈波,吴天麟,韩从辉.慢性前列腺炎的综合治疗分析[J].东南大学学报:医学版,2008,27(1):67-79. |
